Trials / Completed
CompletedNCT00894868
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 798 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin | |
| DRUG | placebo of vildagliptin |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2009-05-07
- Last updated
- 2020-12-17
Locations
93 sites across 15 countries: Czechia, Denmark, Estonia, Germany, Greece, Guatemala, India, Italy, Latvia, Lithuania, Poland, Romania, Russia, Singapore, Slovakia
Source: ClinicalTrials.gov record NCT00894868. Inclusion in this directory is not an endorsement.